» Articles » PMID: 18270325

Ceramide Induces P38 MAPK and JNK Activation Through a Mechanism Involving a Thioredoxin-interacting Protein-mediated Pathway

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2008 Feb 14
PMID 18270325
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Ceramide, a tumor-suppressor lipid, is generated by sphingomyelin hydrolysis or by de novo synthesis when cells are activated by various stress stimuli as well as when cancer cells are subjected to genotoxic chemotherapy. Ceramide may modulate apoptotic signaling pathways; however, its transcription-dependent effects remain unclear. Our data showed that actinomycin D partially inhibited ceramide-induced apoptosis. Using microarray analysis, we found that ceramide up-regulated a tumor suppressor gene called thioredoxin-interacting protein (Txnip). Similarly, the chemotherapeutic agent etoposide induced Txnip expression en route to apoptosis, which was blocked by inhibitors of ceramide production. Txnip colocalized with thioredoxin and reduced its activity, which caused dissociation of thioredoxin from apoptosis signal-regulating kinase 1 (ASK1). Cells expressing ASK1 siRNA were more resistant to ceramide-induced apoptosis. Ceramide caused ASK1-regulated p38 mitogen-activated protein kinase (MAPK) and JNK activation, as well as activation of the endoplasmic reticulum (ER) stress cascade, and pharmacologic or siRNA-mediated inhibition of p38 MAPK or JNK partially reduced ceramide-induced mitochondria-mediated apoptosis. Furthermore, ceramide-induced ASK1, p38, and JNK phosphorylation and cell apoptosis were inhibited by Txnip siRNA transfection. Taken together, we show that ceramide exhibits a mechanism of transcriptional regulation involving up-regulation of Txnip expression, also induced by etoposide, which results in ASK1 activation, ER stress, and p38 and JNK phosphorylation, all leading to apoptosis.

Citing Articles

Evaluation of curcumin nanoparticles of various sizes for targeting multidrug-resistant lung cancer cells via inhalation.

Loo C, Traini D, Young P, Yeung S, Leong C, Lee W Nanomedicine (Lond). 2024; 20(2):141-153.

PMID: 39660666 PMC: 11731332. DOI: 10.1080/17435889.2024.2439241.


Glycosphingolipids in Cardiovascular Disease: Insights from Molecular Mechanisms and Heart Failure Models.

Huang S, Abutaleb K, Mishra S Biomolecules. 2024; 14(10).

PMID: 39456198 PMC: 11506000. DOI: 10.3390/biom14101265.


Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis.

Ramos-Molina B, Rossell J, Perez-Montes de Oca A, Pardina E, Genua I, Rojo-Lopez M Front Endocrinol (Lausanne). 2024; 15:1400961.

PMID: 38962680 PMC: 11220194. DOI: 10.3389/fendo.2024.1400961.


The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control.

Deng J, Pan T, Liu Z, McCarthy C, Vicencio J, Cao L Br J Cancer. 2023; 129(12):1877-1892.

PMID: 37794178 PMC: 10703902. DOI: 10.1038/s41416-023-02442-4.


Defensin1 as a tumor sensitizer for improving chemotherapy: translation from anti-fungal agent to a potential anti-cancer agent.

Pandurangi R, Karwa A, Sagaram U, Henzler-Wildman K, Shah D Front Oncol. 2023; 13:1141755.

PMID: 37305575 PMC: 10251204. DOI: 10.3389/fonc.2023.1141755.